| Budget Amount *help |
¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2013: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2012: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2011: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Research Abstract |
We recently developed AAV vectors that can cross the blood-brain or meningeal-brain barriers. Using these AAV vectors, we have shown beneficial effects in mouse models of neurodegenerative diseases. The early intervention of miR-196a delivered by an AAV vector ameliorated the phenotypes in a mouse model of spinal and bulbar muscular atrophy. A single intracardiac administration of the vector carrying neprilysin gene in a mice model of Alzheimer disease reduced Abeta oligomers, with concurrent alleviation of abnormal learning and memory function. Gene delivery of the RNA-editing enzyme, adenosine deaminase, which acts on RNA 2 (ADAR2) in conditional ADAR2 knockout mice prevented progressive motor dysfunction. These AAV vectors may provide a novel platform for treating neurodegenerative diseases, especially where global transduction of a therapeutic gene into the brain is necessary.
|
